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Background. Chronic infection with hepatitis B virus (HBV) arising in childhood is associated with hepatocellular carcinoma in
adult life. Between 1986 and 1990, approximately 120,000 Gambian newborns were enrolled in a randomised controlled trial to
assess the effectiveness of infant HBV vaccination on the prevention of hepatocellular carcinoma in adulthood. These children
are now in adolescence and approaching adulthood, when the onset of sexual activity may challenge their hepatitis B
immunity. Thus a booster dose in adolescence could be important to maintain long-term protection. Methods. Fifteen years
after the start of the HBV infant vaccination study, 492 vaccinated and 424 unvaccinated children were identified to determine
vaccine efficacy against infection and carriage in adolescence. At the same time, 297 of the 492 infant-vaccinated subjects were
randomly offered a booster dose of HBV vaccine. Anti-HBs was measured before the booster, and two weeks and 1 year
afterwards (ISRCTN71271385). Results. Vaccine efficacy 15 years after vaccination was 67.0% against infection as manifest by
anti-HBc positivity (95% CI 58.2–74.6%), and 96.6% against HBsAg carriage (95% CI 91.5–100%). 31.2% of participants had
detectable anti-HBs with a GMC of 32 IU/l. For 168 boosted participants GMC anti-HBs responses were 38 IU/l prior to
vaccination, 524 IU/l two weeks after boosting, and 101 IU/l after 1 year. Conclusions. HBV vaccination in infants confers very
good protection against carriage up to 15 years of age, although a large proportion of vaccinated subjects did not have
detectable anti-HBs at this age. The response to boosting persisted for at least a year. Trial Registration. Controlled-
Trials.com ISRCTN71271385
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INTRODUCTION
Recent estimates indicate that more than a third of the world’s
population, 2 billion people, have serological evidence of infection
with hepatitis B virus (HBV). Around 360 million people are
chronically infected; 60 million of whom reside in Africa. Up to
a quarter of chronically infected individuals (depending on
background mortality) may die as a result of the infection. It is
estimated that at least half a million deaths per year are due to
hepatitis B infection [1]. 10–15% of all adult male deaths in The
Gambia are estimated to be related to hepatocellular carcinoma
and chronic liver disease.
HBV persists in chronic carriers, who act as the main reservoir for
infection. Transmission of the virus peaks in the first years of life,
related to both perinatal transmission and horizontal transmission
among young children, and again with the onset of sexual activity.
To prevent infection with hepatitis B and its sequelae, routine infant
vaccination against hepatitis B is recommended by the World Health
Organization. Information on the longevity of protection resulting
from the primary course in a highly endemic area, and the
additional benefits (if any) of a booster would greatly facilitate
decisions regarding the need to boost following infant vaccination.
The Gambia Hepatitis Intervention Study (GHIS) was launched
in July 1986 with the objective of evaluating over a period of 40
years the effectiveness of hepatitis B vaccination in the prevention
of hepatitis B infection, chronic liver disease and primary liver
cancer in a population at high risk. Hepatitis B vaccination was
introduced into the national immunisation programme using
a ‘stepped wedge’ trial design. Every few months, one of the
existing vaccinations centres selected at random would start
administering hepatitis B vaccination in addition to the other
infant vaccinations, until countrywide coverage was achieved [2].
Between 1986 and 1990, about 60,000 children received plasma-
derived hepatitis B vaccine (HBVvaxH; Merck, Sharpe & Dohme)
with the other EPI vaccines; and about 60,000 children received
only the regular vaccines in the first year of life. Subsequent
longitudinal and cross sectional surveys of selected samples of the
two groups were carried out over the first 10 years of life.
Follow-up showed that the immune response to vaccination in
infancy was excellent, despite antibody levels waning over the
years. At 9 years of age, 31% of children had anti-HBs titres below
10 IU/l, which is the minimum concentration needed to ensure
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100 IU/l. However, protection against hepatitis B infection and
against chronic carriage in the vaccinated group remained
relatively constant between the age of 4 years and of 9 years
(being 83% and 94% respectively), in spite of this waning of
antibody [3]. Transient infections, which may boost both cellular
and humoral immunity, were noted in one third of infected
children. This continued exposure to the virus among vaccinees
has also been noted in other populations [4]. A small long-term
study from Senegal with a large loss to follow-up reported
efficacies nine to twelve years after vaccination of 63% against
infection and 87% against chronic carriage [5]. One small study in
China also assessed vaccine efficacy after 15 years of age [6]. Since
exposure to infection is limited at this age, it is unclear whether or
not this low level of antibody confers an increased risk of infection
and in particular in the risk of becoming a chronic carrier
following a subsequent challenge, eg through sexual exposure.
Immunological memory persists in spite of non-detectable
antibodies and can produce an adequate response within days.
However, it is not known how long such immunological memory
persists, and the delay prior to activation of the immune system
may offer a window of opportunity for transmission of the virus
[7].
The rise in anti-HBs antibodies following boosting can be
quantified. The subsequent decay can be modelled to estimate the
number of years gained with protective serum antibody levels
.10 IU/l, and thus to estimate the number of anti-HBc antibody
conversions averted.
In a recently completed study in two small Gambian villages,
the protection provided by vaccination in early life against
infection remained stable between the ages of 1–4 (93%) to 10–
14 years (92%), but started to decline at older ages (81% among
the 15–19 years old, 71% among the 20–24 years olds). Protection
against carriage showed a similar trend (still very high at 98% at
10–14 years, 96% at 15–19 year, and 91% among the 20–24 year
olds) [8]. This study used historical control data to estimate
vaccine efficacy. The decline in vaccine efficacy during adoles-
cence may coincide with the onset of sexual activity. We had
already shown that time since vaccination and undetectable
antibody levels following vaccination (,10 IU/l) were the most
powerful risk factors for breakthrough infection (p,0.0001 in both
cases) in adolescence [9]. Previously we had shown that undetect-
able antibody levels in the year preceding sero-conversion to anti-
HBc were also associated with a much increased risk for infection
in children at 7 years of age [10].
This study aimed to evaluate long-term vaccine efficacy of
infant vaccination in a large adolescent sample, as a follow-up
within the original GHIS trial, representative of the general
population, using concurrent unvaccinated controls, and to assess
the immune response to an adolescent booster dose after 2 weeks
and one year in the same population.
METHODS
Participants
Vaccine efficacy and response to boosting were assessed in a cross-
sectional sample of individuals originally recruited into the GHIS
as infants. Recruitment was limited to the catchment areas of the
five health centres in the study where vaccination started only in
1989. Participants were eligible if born between 1 July 1988 and
31 December 1989, and if they could be identified and matched
with the original GHIS database.
In each catchment area, a random sequence of enumeration
areas was generated. Within each enumeration area, fieldworkers
went from compound to compound recording identification details
of potential recruits until the target number for a catchment area
was reached.
Fieldworkers and nurses revisited participants who had been
matched with the original GHIS database to ask for a venous
bloodsample. A random selection of 60% of fully vaccinated
participants was assigned to receive a booster dose of hepatitis B
vaccine (EuvaxH), followed by an additional blood sample to
measure anti-HBs antibodies level 2 weeks afterwards. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see CONSORT S1 and
Protocol S1. All vaccinated subjects, whether boosted or not, were
asked for a final sample to determine anti-HBs antibodies one year
after the first blood sample (figure 1).
Objectives and Outcomes
The primary objective of the follow up was to establish vaccine
effectiveness against anti-HBc and HBsAg positivity. The primary
objective of the nested RCT was to establish the short term (2
weeks) and medium term (1 year) anti-HBs response to a HBV
boost in adolescence. Anti-HBs antibody levels two and 52 weeks
after a booster dose enable an assessment of the duration of
a response, as well as assessing the proportion of vaccines with and
without an anamnestic response.
Laboratory
Anti-HBc and anti-HBs antibodies were detected using a commer-
cial EIA (ETI-AB-Corek Plus and ETI-AB-AUK respectively,
DiaSorin, Saluggia, Italy) according to the manufacturer’s
instructions. The level of detection of anti-HBs was 10 IU/l.
Samples which were anti-HBc positive, were tested for HBsAg
by Determine
TM HBsAg (Abbott Laboratories), a visually read,
qualitative immunochromatographic assay. All those who tested
HBsAg positives were retested after 6 months to confirm carrier
status. Samples which were HBsAg positive, were tested for
HBeAg using an enzyme immunoassay [EIA] (Equipar Diagnos-
tici, Saronno (Va), Italy).
Definitions
If one or two doses of HBV were recorded in the GHIS database
the participant was considered partially vaccinated; if three or four
doses were received this was defined as fully vaccinated.
Infection was defined by the presence of anti-HBc with at least
30% inhibition, as stipulated by the manufacturer. If infection was
found in a person vaccinated in infancy, this was considered
a breakthrough infection. Chronic carriage was defined as testing
HBsAg positive at both the initial and the 12 month follow-up
survey.
An early anamnestic response to the booster dose was defined as
a four fold or greater rise in anti-HBs antibody within two weeks of
the booster dose, or for children with no detectable antibody in the
first sample, an anti-HBs antibody level $10 IU/l within two
weeks of the booster dose, in line with recently published CDC
methods [11]. A long-term anamnestic response was defined as at
least a two fold rise in anti-HBs antibody one year after boosting,
or if no detectable antibody response at baseline, an anti-HBs
antibody level of $10 IU/l.
Sample size
Based on the vaccine efficacy data from previous follow-up of the
GHIS after 9 years (83% against infection, 94% against carriage)
[3] and assuming that among the unvaccinated group the
prevalence of infection had risen to 75% and the prevalence of
Protection 15 yrs after HBV
PLoS ONE | www.plosone.org 2 August 2007 | Issue 8 | e753carriage to 12%, and that in the vaccinated group anti-HBc
prevalence had risen to 20% and persistent HBsAg positivity to
2%, we calculated that we needed to recruit 500 participants in
each group (vaccinated and unvaccinated) to estimate a vaccine
efficacy against infection of 73% (CI 68–78) and against carriage
of 83% (CI 70–93). Increasing the sample size had only a minor
effect on the width of the confidence intervals. Different
assumptions result in different efficacy estimates, but do not
significantly affect the width of the confidence intervals.
As we assumed that loss to follow-up after one year might be
larger in the vaccinated group randomised to a booster (due to the 2
week bleed among the boosted group), we calculated that with
a distribution of 300 boosted and 200 not boosted, and assuming
a 20% loss to follow-up, we would be able to measure antibody
responses after 52 weeks in 200 boosted and 160 unboosted
vaccines, which would giveus over 90% power to detect a significant
difference in a protective level of antibodies (defined as anti-
HBs.10 IU/ml) between the boosted and unboosted group.
This sample size was adjusted based on assumptions of
percentage which could be matched to the original database
(50%), matched participants found on follow up (90%) and then
consenting to be bled (90%; 80% for the bleed two weeks after the
booster; 60% for the bleed one year later). Thus, a total of 3500
potentially eligible 15 year olds were estimated as necessary for
initial recruitment. For each of the five catchment areas, a sample
size proportional to size was calculated.
Figure 1. Flowchart HBV booster allocation.
doi:10.1371/journal.pone.0000753.g001
Protection 15 yrs after HBV
PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e753Matching and data management
A questionnaire collected personal and demographic information
from all potential recruits. Items included names for both
participants and parents, date and place of birth, Infant Welfare
Card (IWC) number, ethnic group and date of previous hepatitis
vaccination if recorded on the IWC.
Data were double entered and validated directly into a table in
an Access database (Microsoft) also containing a data table with
details of the original GHIS cohort. A sequence of queries was run
to match recruits with GHIS participants. Data for non-matching
recruits were imported to Reclinc2 (IARC) where further non-
specific matching techniques were used involving soundex and
cross matching of all family names.
Matched recruits were defined as confirmed or probable
matches. Confirmed matches by definition had the same
combinations of IWC number and date of birth whilst names
were generally similar with allowances for differences in spelling or
abbreviations. For the purposes of the follow up only confirmed
matches were included.
Laboratory data were exported directly from the assay reader to
Excel (MICROSOFT) and directly imported into the study
database.
Randomisation
In each area from which participants were recruited, stratified by
sex, a random 60% sample was identified, using computer
generated lists. Laboratory staff responsible for the outcome
measurements were blinded to the allocation.
Statistical methods
Data were analysed using Stata 8.0 (Stata Corp, Texas, USA).
Surface antibody levels were log-transformed and a Geometric
Mean Concentration (GMC) calculated where a response was
measured (anti-HBs $10 IU/l). Vaccine efficacy was calculated as
1-(prevalence in the vaccinated/prevalence in the unvaccinated).
Statistical significance of differences between groups was assessed
with a Pearson Chi-square test or by Fisher’s exact test, as
appropriate. A p-value,0.05 was considered to denote statistical
significance.
Logistic regression was used to estimate crude and adjusted
odds ratios for an anamnestic response after boosting by number
of doses received in infancy and by core-positivity prior to the
boost.
Ethics
The study was approved by the Gambia Government/MRC
Ethics Committee. All participants and their guardians gave
signed informed consent. The incorporated trial assessing the
effect of boosting or not among infant vaccinnees
(ISRCTN71271385) was monitored to ensure it complied with
Good Clinical Practice guidelines. Written feedback of results was
provided to all participants.
RESULTS
Participants
Between February and July 2004, 3709 potentially eligible
participants were identified in the selected areas. For 2147
(57.9%) a satisfactory match was found in the original database.
An absolute match was confirmed for 1414, of which 1225 were of
the correct age. Of these, 1000 (81.6%) were traced and consented
to a blood sample being taken. Of these, 492 (49.2%) had been
fully vaccinated (320, 65.0% of them with 4 doses, the remainder
with 3 doses), 84 (8.4%) partially, and 424 (42.4%) were not
vaccinated as infants.
Of the fully vaccinated participants who consented to a blood
sample being taken, 297 out of 492 were randomly allocated to
receive a booster dose. Of these 255 out of 297 (85.6%) donated
a sample after two weeks. After one year, a sample was received
from 264 out of the 297 (88.9%) of those boosted and 182 out of
195 (93.3%) of the unboosted subjects (figure 1)..
Table 1. Baseline characteristics of participants identified.
..................................................................................................................................................
Vaccinated Partially vaccinated Unvaccinated
All Boosted Not boosted
Recruited 492 297 195 84 424
Female n (%) 272 (55.3%) 162 (54.6%) 110 (56.7%) 53 (63.1%) 228 (53.8%)
Mean age (sd) 14.9 (0.4) 14.9 (0.4) 14.9 (0.4) 15.0 (0.4) 15.6 (0.3)
Ever jaundiced 39 (7.9%) 24 (8.1%) 15 (7.7%) 4 (4.8%) 38 (9.0%)
doi:10.1371/journal.pone.0000753.t001
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Table 2. Vaccine efficacy against infection (anti-HBc positive) and chronic carriage (HBsAg positive) among 15 year old Gambians,
according to hepatitis B infant vaccination status.
..................................................................................................................................................
Fully vaccinated Partially vaccinated Unvaccinated
Infection (n/N, % 95% CI) 87/492 (17.7%, 14.4–21.3) 19/84 (22.6%, 14.2–33.0) 226/424 (53.3%, 48.4–58.1)
VE (95% CI) 67.0 (58.2–74.6) 57.7 (37.2–76.8) Ref
Chronic carriage (n/N, % 95% CI) 2/492 (0.4%, 0.04–1.5) 1/84 (1.2%, 0.03–6.5) 51/420 * (13.2%, 10.1–16.8)
VE (95% CI) 96.6 (91.5–100) 90.1 (69.9–100) ref
*four participants were HBsAg positive during the first screening, but could not be traced to confirm chronic carriage
VE: vaccine efficacy
CI: confidence interval
doi:10.1371/journal.pone.0000753.t002
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older than the vaccinated infants. There was a balanced distribution
within the boosted and unboosted participants (table 1).
Vaccine efficacy
Of the unvaccinated population, 226 out of 424 (53.3%, 95% CI
48.4–58.1) were anti-HBc positive; 19 out of 84 (22.6%, 95% CI
14.2–33.0) of the partially vaccinated group, and 87 out of 492
(17.7%, 95% CI 14.4–21.3) of the fully vaccinated children.
Among the fully vaccinated children, there was no difference in
prevalence of anti-HBc positivity among those who had received
three or four doses in infancy (16.8% vs 18.1%, p=0.7); nor
among the partially vaccinated children who had received one or
two doses (25.0% vs 21.2%, p=0.7). Thus, 15 years after
vaccination, vaccine efficacy against infection of the fully
vaccinated children versus unvaccinated children was 67.0%
(95% CI 58.2–74.6). Vaccine efficacy against infection for the
partially vaccinated children versus unvaccinated children was
lower at 57.7% (37.2–76.8) (table 2).
Of those infected, 56 of the unvaccinated, one of the partially
vaccinated and two of the fully vaccinated children were HBsAg
positive. To assess if these were chronic carriers, a follow-up
sample was collected one year later. Four out of 56 unvaccinated
HBsAg positive participants could not be traced after one year to
determine whether they were chronic carriers. All but one of the
remaining 52 unvaccinated subjects who could be traced were
confirmed as chronic carriers. Excluding the 4 unvaccinated
subjects lacking confirmation of chronic HBsAg positivity, vaccine
efficacy of the fully vaccinated against carriage was 96.6% (96%
CI 91.5–100), and for the partially vaccinated versus unvaccinated
was 90.1% (95% CI 69.9–100) (table 2).
Baseline anti-HBs data and response to a booster
dose
Baseline anti-HBs level could be determined for 570 subjects. At
the onset of the study, 392 out of 570 (68.8%, 95% CI 64.8–72.6)
participants had undetectable surface antibody levels, significantly
more among unvaccinated subjects (99/126, 78.6%, 95% CI
70.4–85.4) than among infant-vaccinated subjects (254/382,
66.5%, 95% CI 61.5–71.2, p-value 0.01), but did not differ
between the vaccinated groups randomised to a booster dose or
not (table 3). The percentage of individuals with detectable
antibody was highest among the partially-vaccinated group (23/
62; 37.1% 95% CI 25.1–100). The overall GMC was 31.6 IU/l
(95% CI 26.7–37.4), and did not differ significantly between the
groups (table 4).
Two weeks after the booster dose, 7/217 (3.2%, 95% CI 1.3–
6.5) of all boosted participants had undetectable anti-HBs, versus
148/225 (65.8%, 95% CI 59.2–72.0) prior to the boost; while 79/
217 (36.4%, 95% CI 30.0–43.2) had an anti-HBs level above
1000 IU/l (table 3). Of the participants with undetectable
antibodies at baseline, 7/114 (6.1%, 95% CI 2.5–12.2) still had
no detectable anti-HBs response 2 weeks after the boost.
For 181 out of 297 of the boosted participants anti-HBs
responses were measured at baseline and two weeks after the
Table 3. Number (%, 95% CI) of vaccinated and boosted subjects in each anti-HBs category prior to boosting, and 2 weeks and 1
year afterwards.
..................................................................................................................................................
Pre boost 2/52 Post boost 12/12 post boost
Anti-HBs
in IU/l Unvaccinated
Vaccinated to be
boosted
Vaccinated not to be
boosted Boosted Not-boosted
n 126 225 157 217 264 182
,10 99 (78.6%) (70.4–85.4) 148 (65.8%) (59.2–72.0) 106 (67.5%) (59.6–74.8) 7 (3.2%) (1.3–6.5) 57 (21.6%) (16.8–27.0) 139 (76.4%) (69.5–82.3)
10–99 25 (19.8) (13.3–27.9) 65 (28.9%) (23.1–35.3) 46 (29.3%) (22.3–37.1) 24 (11.1%) (7.2–16.0) 117 (44.3%) (38.2–50.5) 34 (18.7%) (13.3–25.1)
100–999 2 (1.6) (0.2–5.6) 11 (4.9%) (2.5–8.6) 5 (3.2%) (0.1–7.3) 107 (49.3%) (42.5–56.2) 77 (29.2%) (23.8–35.1) 9 (5.0%) (2.3–9.2)
$1000 0 1 (0.4%) (0.01–2.5) 0 79 (36.4%) (30.0–43.2) 13 (4.9%) (2.6–8.3) 0
doi:10.1371/journal.pone.0000753.t003
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Table 4. Proportion (95% confidence interval) with detectable surface antibody levels and GMC of participants by infant
vaccination and adolescent boosting status.
..................................................................................................................................................
Vaccinated Partially vaccinated Not vaccinated
All Boosted Not boosted p-value
Baseline 382/492 (77.6%) 225/297 (75.7%) 157/195 (80.1%) 62/84 (73.8%) 126/424 (29.7%)
Anti-HBs $10 IU/l 128 (33.5%) (28.8–38.5) 77 (34.2%) (28.0–40.8) 51 (32.5%) (25.2–40.4) 0.7 23 (37.1%) (25.1–50.0) 27 (21.4%) (14.6–29.6)
GMC if anti-HBs detected 31.4 (26.0–38.0) 34.8 (26.9–44.9) 27.0 (20.2–36.0) 0.2 45.8 (22.6–92.6) 23.6 (17.4–32.0)
2 weeks after boost - 217/297 (73.1%) - - -
Anti-HBs $10 IU/l - 210 (96.8%) (93.5–98.7) - - -
GMC if anti-HBs detected - 498.3 (424.0–585.6) - - -
1y e a rafter boost 446/492 (90.6%) 264/297 (88.9%) 182/195 (93.3%) - -
Anti-HBs $10 IU/l 250 (56.1%) (51.3–60.7) 207 (78.4%) (73.0–83.2) 43 (23.6%) (17.7–30.5) ,0.001 - -
GMC if anti-HBs detected 76.2 (64.0–90.7) 89.5 (74.0–108.3) 35.1 (24.2–51.0) 0.0001
doi:10.1371/journal.pone.0000753.t004
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early anamnestic response. In this group the GMC had increased
from 36 IU/l (95% CI 27–47) to 524 IU/l (95% CI 441–621).
Among the vaccinated boosted subjects who were anti-HBc
positive at baseline, 12/17 (70.6%, 95% CI 44.0–89.7) showed an
early anamnestic response, compared to 155/164 (94.5%, 95% CI
89.8–97.5) of boosted subjects who were anti-HBc negative at
baseline(p,0.001).
One year after the boost, 57 out of 264 (21.6%, 95% CI 16.8–
27.0) of boosted individuals had undetectable surface antibodies
(table 3). Of the 7 participants who did not have a response two
weeks after the booster dose, five still had undetectable antibody
levels, but two now had a measurable anti-HBs concentration
(14.1 and 101.7 IU/l respectively).
A long-term anamnestic response was detected in 137 out of 197
(69.5%, 95% CI 62.6–75.9) of boosted participants. Among the 16
vaccinated boosted subjects who were anti-HBc positive, 6 (37.5%,
95% CI 15.2–64.6) showed a long-term anamnestic response,
compared to 131 out of the 181 (72.4%, 95% CI 65.2–78.7) of
those who had remained anti-HBc negative (p=0.001).
In total, anti-HBs responses were evaluated at all three points (at
baseline before boosting, two weeks and one year afterwards) in
168 of the boosted subjects. The GMC of this group at baseline
was 38 IU/l (95% CI 29–50), which increased after two weeks to
524 IU/l (95% CI 438–626) and fell to 101 IU/l (95% CI 79–129)
at 1 year. Among the 144 unboosted participants bled at baseline
and one year afterwards, the GMC remained similar at 29 and
28 IU/l respectively.
Anti-HBc positivity was associated with significantly reduced
odds ratio (OR) of having an early and a long-term anamnestic
response. In a multivariable analysis, adjusting for sex, area, and
number of doses, the OR was further reduced. Anti-HBc-positivity
was also associated with a significantly reduced OR of having an
anamnestic response after one year. Those who had received four
doses in infancy had an increased OR for an anamnestic response
after two weeks which remained borderline significant after one
year compared to those who had received three doses (table 5).
Adverse events
No adverse events related to receiving a booster dose were noted.
DISCUSSION
Within the GHIS population, vaccine efficacy of infant HBV
vaccination against carriage has remained high at 15 years of age,
as was also observed in a previous study at 9 years of age [3] (94%
and 97% respectively), while vaccine efficacy against infection
declined from 82% at 9 years of age to 67% at 15 years of age. In
this study, over two thirds of the 15 year olds did not have
detectable anti-HBs levels, which is similar to the previous
observations at 9 years of age. As expected, following a booster
vaccination, a marked increase in surface antibody was seen; with
97% of boosted participants having detectable antibody after 2
weeks, and nearly 80% still a year after the booster, compared to
a third prior to the boost. This low pre-boost antibody level
suggests that either limited natural exposure to HBV with
subsequent subclinical boosting had occurred during the early
teenage years; or that natural boosting did not result in a sustained
anti-HBs response.
In spite of the excellent response to boosting in general, 3% of
boosted participants did not mount a detectable antibody response
following a booster dose of HBV. It is possible that these
individuals may have been primary non-responders as a study in
two rural Gambian villages showed that two months after the last
infant vaccination, 5% of children did not mount a detectable anti-
HBs response and were therefore considered primary non-
responders to the HBV vaccine [12]. On the other hand, of the
7 non-responders among the boosted subjects, two participants did
show an effective response a year later. These 2 may have
mounted a primary response to this single dose of vaccine. It is also
possible that sub-clinical exposure had occurred during the year,
which boosted the antibody response. Alternatively, some pre-
sumed non-responders could actually be slow responders,
corresponding with a low rate of memory accumulation [7].
It is remarkable that vaccine efficacy against chronic carriage
among the group who were only partially vaccinated was rather
similar to that of the group who had been fully vaccinated. Several
studies have already shown that adolescents and adults vaccinated
with two or even with one dose, had similar short-term antibody
responses to those vaccinated with 3 doses [13,14,15,16,17,18,19].
We have also recently demonstrated that children vaccinated with
two doses rather than three, had similar vaccine efficacy against
infection and carriage after 4 to 7 years (submitted). This study
now suggests that those only partially vaccinated against HBV in
infancy not only have similar antibody responses as those who
received at least 3 doses, but may have also a similar long-term
vaccine efficacy as those fully vaccinated for up to 15 years.
Nevertheless, it should be noted that the lower limit of the
confidence interval is only around 70% versus the greater than
90% in the fully vaccinated; this study is too small to establish
equivalence of protection.
These findings are of relevance for the understanding of the
long term protection of HBV vaccine in infancy, in a population
still heavily exposed to HBV as suggested by similar anti-HBs
antibody levels at baseline in both vaccinated and unvaccinated
groups, and by the observation that over half of the unvaccinated
subjects were positive to anti-HBc.
This study also showed that it is possible to trace records for
a large proportion of infants 15 years after recruitment, in a sub-
Saharan setting in the absence of consistent identifying documen-
tation. The main outcome of the GHIS study is only expected to
occur 40 years following the start of the infant vaccination
Table 5. Crude and adjusted odds ratios (OR, 95% CI) for a short term (2 weeks) and a long term (1 year) anamnestic response after
boosting.
..................................................................................................................................................
Short term Long term
Variable Crude Adjusted Crude Adjusted
Anti-HBc positive vs anti-HBc negative 0.1 (0.04–0.45) 0.05* (0.01–0.3) 0.2 (0.08–0.7) 0.2* (0.07–0.6)
Four doses of vaccine vs three doses of vaccine 2.5 (0.8–7.6) 5.2** (1.3–20.7) 1.6 (0.9–3.0) 1.9** (1.0–3.8)
*Odds ratio’s adjusted for sex, area, number of doses
**Odds ratio’s adjusted for sex, area, core-positivity
doi:10.1371/journal.pone.0000753.t005
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with hepatocellular carcinoma in the GHIS database to ascertain
their vaccination status (GHIS). Using advanced iterative search
strategies, nearly 60% of adolescences who reported that they were
in the correct age range of the GHIS were identified in the
database, although for a third of this group, it was not possible to
confirm the match mainly due to the recruit not knowing their
date of birth. It is expected that most of this group could be fully
matched based on the foot- and palm prints, which were collected
from the infants at the start of the trial to enable final matching.
In view of the low levels of circulating antibody in adolescence,
there is uncertainty if the high vaccine efficacy against carriage can
be maintained once infant vaccines become exposed to HBV via
sexual routes. In fact, despite high natural exposure to circulating
HBV infection, it is not clear whether natural boosting can sustain
protection or not over time. The excellent short-term response to
boosting suggests immunological memory is well maintained [20].
A recent consensus statement based on published evidence
concluded that no booster was required for 15 years after primary
vaccination [21]. However, this was based on a single publication
from China where 54 unvaccinated and 52 vaccinated children
were followed up at this age [6]. The authors themselves
acknowledged that their study had serious limitations especially
due to the incomplete follow-up and the alteration of the original
cohort. Furthermore, since risk of infection associated with
adolescence may differ in other areas of the world, it is unclear
how far this finding can be generalised. Therefore, it remains to be
evaluated whether a memory response would be sufficient to
prevent infection and carriage following sexual exposure in
adulthood. Our study showed that nearly 20% of those fully
vaccinated had become anti-HBc positive, which gave a significant
reduction in the likelihood of having a short term and a long-term
anamnestic response. Once more vaccines against sexually trans-
mitted infections become available (such as HPV and HSV)
adolescents are likely to be a major target group for them. HBV
booster vaccination will be a major candidate for evaluation.
SUPPORTING INFORMATION
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